Core Insights - Definitive Healthcare reported third quarter results that met or exceeded the high end of their guidance, with Adjusted EBITDA surpassing expectations by $2 million [3] - The company is focused on operational initiatives and investments to enhance performance over time, showing improvements in new customer acquisition and retention rates [3] Financial Highlights - Revenue for Q3 2025 was $60.0 million, a decrease of 4% from $62.7 million in Q3 2024 [6] - Net loss was $(17.8) million, or (30)% of revenue, compared to $(187.8) million in Q3 2024, which included goodwill impairment charges of $228.2 million [6] - Adjusted Net Income was $9.7 million, down from $15.4 million in Q3 2024 [6] - Adjusted EBITDA was $18.9 million, or 32% of revenue, compared to $20.6 million, or 33% of revenue in Q3 2024 [6] Business and Operating Highlights - The company secured new customer wins across all end-markets, providing critical data and insights [4][7] - A large multi-national biopharma selected Definitive Healthcare to enhance their medical affairs operations, demonstrating the value of their Key Opinion Leader datasets [7] - A medical device company transitioned to Definitive Healthcare after their previous provider failed to deliver necessary insights, highlighting the company's competitive advantage [7] Guidance and Outlook - For Q4 2025, revenue is expected to be in the range of $59.0 – $60.0 million, with Adjusted Operating Income anticipated between $13.5 – $14.5 million [8] - Adjusted EBITDA is projected to be in the range of $16.0 – $17.0 million, with an adjusted EBITDA margin of 27 – 29% [8] - Full year 2025 revenue is expected to be between $239.0 – $240.0 million, raising the bottom end of the prior range by $2.0 million [15]